Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL442201 | 0.83 | CHRNB2 (0.31) | CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL9298 | 0.71 | TRPA1 (0.33) | — | |
| SCHEMBL19445110 | 0.69 | TDP1 (0.33) | — | |
| SCHEMBL24061467 | 0.69 | CHRNB2 (0.31) | CHRNB2CHRNA4 | |
| SCHEMBL2472934 | 0.67 | CLK1 (0.36) | — | |
| SCHEMBL71577 | 0.67 | — | — | |
| SCHEMBL20470466 | 0.67 | SIGMAR1 (0.33) | CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL4624522 | 0.65 | — | — | |
| SCHEMBL22898199 | 0.63 | CYP19A1 (0.36) | — | |
| SCHEMBL29787065 | 0.62 | GAA (0.32) | CHRNB2CHRNA4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245156-A1 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-10-06 | — | — | US | claimed |
| WO-2010077740-A2 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYTOKINE PHARMASCIENCES, INC. (US) | 2010-07-08 | — | — | WO | claimed |
| CN-101693672-B | Peptidomimetic protease inhibitors | VERTEX PHARMA | 2014-11-12 | — | — | CN | disclosed |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| CN-101538246-B | Pyrimidine amide compounds as PGDS inhibitors | AVENTIS PHARMA INC | 2014-07-16 | — | — | CN | disclosed |
| EP-2368877-B1 | Peptidomimetic protease inhibitors and intermediates for their preparation As treatment for HCV infection | VERTEX PHARMA (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-1958956-B1 | Peptidomimetic protease inhibitors | VERTEX PHARMA (US) | 2013-12-11 | — | — | EP | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-8529882-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| CN-101646656-B | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI AVENTIS SPA | 2013-08-14 | — | — | CN | disclosed |
| CN-103232381-A | Peptidomimetic protease inhibitors | VERTEX PHARMA | 2013-08-07 | — | — | CN | disclosed |
| WO-2001081310-A1 | 1-AROYL-PIPERIDINYL BENZAMIDINES | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-01 | — | — | WO | disclosed |
| EP-1144367-A1 | ALPHA-SUBSTITUTION OF UNPROTECTED BETA-AMINO ESTER COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001066098-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | AVENTIS PHARMA DEUTSCHLAND GMBH | 2001-09-13 | — | — | WO | disclosed |
| US-6277865-B1 | ANTICOAGULANTS | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-08-21 | — | — | US | disclosed |
| EP-1089988-A1 | FLUOROPHENYL RESIN COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2001010799-A1 | METHODS FOR PREPARING N-[(ALIPHATIC OR AROMATIC)CARBONYL)]-2-AMINOACETAMIDE COMPOUNDS AND FOR CYCLIZING SUCH COMPOUNDS | AVENTIS PHARMACEUTICAL PRODUCTS INC. (US) | 2001-02-15 | — | — | WO | disclosed |
| US-6133409-A | REACTING A SOLID SUPPORT-BOUND N-ALKYLATED HYDROXAMIC ACID WITH A CARBON-NITROGEN CLEAVING ORGANOMETALLIC COMPUND TO LIBERATE THE PRODUCT KETONE | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-10-17 | — | — | US | disclosed |
| WO-2000040547-A1 | α-SUBSTITUTION OF UNPROTECTED β-AMINO ESTER COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-1999067228-A1 | FLUOROPHENYL RESIN COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PREP, PEPD | CHRNB2 4869/4885CHRNA4 4883/4885SIGMAR1 1810/4885 |
| US-20110245156-A1 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | DDX5, SAMHD1, EIF2AK2 | CHRNB2 4719/4885CHRNA4 4705/4885SIGMAR1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.